ClinicalTrials.gg
Not yet recruitingNCT07675720Updated Jun 30, 2026

Concurrent Training vs Soleus Push-Ups on Neurogenesis-Related Biomarkers in Diabetic Neuropathy Patients

An interventional study of Concurrent Training and Soleus Push-ups in Diabetic Peripheral Neuropathy Type 2, sponsored by Riphah International University. Not yet recruiting at 1 site in Pakistan. Open to participants aged 40 Years to 65 Years. Per ClinicalTrials.gov, last updated 2026-06-30.

Sponsored by Riphah International University · Not applicable, Interventional, and Treatment

How we know

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Not applicable
Study type
Interventional
Enrollment
99
Allocation
Randomized
Ages
40 Years to 65 Years
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-22

Among 24 studies in Diabetic Neuropathies by Riphah International University — 7 open to participants now, 7 under way, none of them phase 3. Diabetic Neuropathies · Riphah International University.

Planned enrollment
3rd of 24
99 · median 44
Started
2026
with 3 others
No phase
24 of 24
7 open now
Registered
22nd of 24
by date

Among the 24 studies in Diabetic Neuropathies by Riphah International University, this one is the 3rd largest by planned enrollment, is one of 4 that started in 2026, is one of 24 with no phase, and was the 22nd registered.

Diabetic Neuropathies

539 studies on the registry are indexed under Diabetic Neuropathies; 80 are open to participants now.

Browse Diabetic Neuropathies studies →

Open to participants now

7 of the 24 studies in Diabetic Neuropathies by Riphah International University are open now, in 1 country. Recruiting first, the newest first:

1 more — sign in →

By country, each count listing its studies:

All 7 open studies →

Where they have run

Who these studies take

Of the 52 Diabetic Neuropathies studies recruiting now, 21 (40%) set no upper age limit and 24 (46%) stop at 75 or younger; 6 take children under 18; 3 take healthy volunteers.

This study: 40 Years to 65 Years · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 24 studies in Diabetic Neuropathies by Riphah International University, or all of them as a file.
02

Study summary

This study will examine how two types of exercise programs affect nerve health in people with diabetic peripheral neuropathy. Diabetic peripheral neuropathy is a common complication of type 2 diabetes that can cause numbness, pain, balance problems, and reduced quality of life. Exercise is often recommended for people with diabetes, but it is not yet clear which types of exercise are most effective for improving nerve function.

In this randomized controlled trial, participants with type 2 diabetes and confirmed peripheral neuropathy will be assigned to one of three groups. One group will perform a combined program of aerobic and resistance exercises (concurrent training). Another group will perform soleus push-up exercises, a seated ankle movement designed to activate the soleus muscle and improve glucose metabolism. The third group will continue with standard diabetes care and general lifestyle advice without a structured exercise program.

The study will evaluate whether these exercise interventions influence biological markers related to nerve repair and neuroplasticity, including brain-derived neurotrophic factor (BDNF), nerve growth factor (NGF), and the Schwann cell marker S100B. In addition, the study will assess changes in neuropathy symptoms, balance and postural stability, blood sugar control, and quality of life.

Participants will complete assessments before the intervention and again during follow-up after the exercise program. The findings of this study may help identify effective and feasible exercise strategies to support nerve health, improve physical function, and reduce the impact of diabetic peripheral neuropathy.

03

Conditions studied

  • Diabetic Peripheral Neuropathy Type 2

Keywords

  • Diabetic Neuropathies
  • Exercise Therapy
  • Neurogenesis
  • Diabetes Mellitus, Type 2
  • Resistance Training
  • Aerobic Exercise
  • Brain-Derived Neurotrophic Factor
  • Nerve Growth Factor
  • Quality of Life
04

Who can participate

Ages eligible
40 Years to 65 Years
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Age 40-65 years
  • Diagnosed Type 2 Diabetes Mellitus (T2DM) Confirmed diagnosis of T2DM for at least 5 years.
  • Confirmed Diabetic Peripheral Neuropathy (DPN)

Diagnosis is based on clinical evaluation and scoring tools such as:

  • Michigan Neuropathy Screening Instrument (MNSI) Cut-off value of ≥4 for Part A (History)(104) Cut-off value of ≥2 from Part B (Examination)(105)
  • Vibration Pressure Threshold (≥25 Volts)(106)

    • between 6.5% and 9.0% Reflecting moderate glycemic control, patients with extremely poor control were excluded for safety.
    • Stable medication regimen No changes in antidiabetic, antihypertensive, or neuropathy medications in the past 3 months.
    • Sedentary or low physical activity level Based on standard questionnaires (International Physical Activity Questionnaire - IPAQ), not currently engaged in structured exercise programs.
    • Ability to walk independently To ensure safety during aerobic or resistance exercise (for Group A).
    • Able to understand and follow instructions
    • Consent to participate and comply with study protocol
    • Written , obtained before randomization

Exclusion criteria

Exclusion Criteria:

  • History of recent cardiovascular events Includes myocardial infarction, stroke, or any cardiac intervention within the past 6 months.

    • Uncontrolled hypertension Blood pressure ≥160/100 mmHg at rest.
    • Severe musculoskeletal disorders or physical disability Including joint deformities, fractures, or amputation that limit the ability to perform exercise.
    • Severe diabetic foot ulcers or active lower limb infection Increases risk during lower limb activity or exercise.
    • End-stage renal disease (CKD stage 4 or higher) Associated systemic complications may confound study outcomes or affect safety.
    • Severe retinopathy or proliferative diabetic eye disease Exercise may pose risks such as retinal hemorrhage.
    • Current Smoker, tobacco or alcohol consumer. That may affect the blood biomarkers.
    • Cognitive impairment or psychiatric disorders That may affect understanding, compliance, or safety during exercise.
    • Participation in a structured exercise program within the last 3 months To avoid training-induced bias and ensure a sedentary baseline.
    • Chronic inflammatory or conditions Conditions like rheumatoid arthritis or lupus may alter neurotrophic biomarkers.
    • Use of medications affecting neurogenesis or metabolism Such as , antipsychotics, or .
    • Diagnosed sleep disorder
    • That may affect the outcomes of the intervention.
    • Pregnancy or lactation Due to altered physiology and ethical concerns.
Terms in these criteria, in plain language(5)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

HbA1c

A blood test of average blood sugar over the past two to three months, given as a percentage or in mmol/mol. 6.5% (48 mmol/mol) or more is the usual threshold for diabetes, normally confirmed by a second test.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

Autoimmune disease

A condition in which the immune system attacks the body’s own tissues, such as rheumatoid arthritis, lupus, psoriasis, type 1 diabetes or inflammatory bowel disease.

Immunotherapy studies often leave out active autoimmune disease, and some name exceptions, such as thyroid disease on replacement hormone. Check the exceptions this study lists.

Corticosteroids (steroids)

Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.

Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.

Immunosuppression

A weakened immune system. It can come from an illness, such as HIV or some blood cancers, or from medicines that turn the immune system down, for example after an organ transplant or for an autoimmune disease; steroids at higher doses count.

Read whether the line is about a condition or about medicines, and which medicines and doses it means.

05

Study design

Phase
Not applicable
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Double (Participant, Outcomes assessor)
Enrollment
99 participants (estimated)

Study arms

  • Active comparator
    Concurrent Training Group (CT)

    Participants will undergo a combined aerobic and resistance exercise program.

    Other: Concurrent Training

  • Experimental
    Soleus Push-Up Group (SPU)

    Participants will perform seated plantar-flexion exercises targeting the soleus muscle, using a controlled movement protocol modeled after the soleus push-up method.

    Other: Soleus Push-ups

  • No intervention
    Control Group

    Participants will receive standard diabetes care and general lifestyle advice without structured exercise intervention.

Interventions

  • OtherConcurrent Training

    Combined aerobic and resistance exercise program.

    Also known as: Exercise

  • OtherSoleus Push-ups

    Seated plantar-flexion exercises targeting the soleus muscle, using a controlled movement protocol

    Also known as: Exercise

06

What researchers measure

Primary outcomes

  1. BDNF (Brain-Derived Neurotrophic Factor)

    Serum Brain-Derived Neurotrophic Factor (BDNF) concentration will be measured quantitatively using a commercially available enzyme-linked immunosorbent assay (ELISA) kit at baseline, 4 weeks, and 8 weeks. BDNF is a neurotrophic factor involved in neuronal survival, synaptic plasticity, and exercise-induced neuroplasticity. Changes in circulating BDNF levels will be used as a primary biomarker of exercise-induced neuroplasticity and neurogenesis-related biological activity. Higher serum BDNF concentrations are considered indicative of greater neurotrophic activity and potential enhancement of neuroplastic processes.

    Time frame: From enrollment to 4 weeks and then to the end of treatment at 8 weeks.

  2. NGF (Nerve Growth Factor)

    Serum Nerve Growth Factor (NGF) concentration will be measured quantitatively using a commercially available enzyme-linked immunosorbent assay (ELISA) kit at baseline, 4 weeks, and 8 weeks. NGF is a key neurotrophic factor involved in the survival, maintenance, and regeneration of peripheral neurons. It plays a fundamental role in peripheral nerve repair and axonal regeneration following nerve injury. Changes in circulating NGF levels will be used as a primary biomarker of peripheral nerve regeneration and neuroregeneration-related biological activity. Higher serum NGF concentrations are considered indicative of enhanced neurotrophic support and regenerative potential of peripheral nerves.

    Time frame: From enrollement to 4 weeks and then after 8 weeks of intervention

  3. S100B (Schwann Cell Marker)

    Serum S100 Calcium-Binding Protein B (S100B) concentration will be measured quantitatively using a commercially available enzyme-linked immunosorbent assay (ELISA) kit at baseline, 4 weeks, and 8 weeks. S100B is a calcium-binding protein that is expressed by Schwann cells in the peripheral nervous system and plays an important role in peripheral nerve repair, remyelination, and axonal regeneration. Changes in circulating S100B levels will be used as a primary biomarker of Schwann cell activity and peripheral nerve regeneration. Higher serum S100B concentrations are considered indicative of increased Schwann cell-mediated neuroregenerative activity.

    Time frame: From enrollment to 4 weeks and then after 8 weeks of intervention

Secondary outcomes

  1. Michigan Neuropathy Screening Instrument (MNSI)

    Neuropathy severity will be assessed using the Michigan Neuropathy Screening Instrument (MNSI), a validated instrument for screening and evaluating diabetic peripheral neuropathy. The MNSI consists of two components: (1) a 15-item patient-reported symptom questionnaire (History; Part A) and (2) a standardized physical examination (Part B) that assesses foot appearance, ulceration, ankle reflexes, and vibration sensation. Assessments will be performed at baseline, 4 weeks, and 8 weeks. The MNSI History score ranges from 0 to 13, with a score of ≥4 indicating the presence of diabetic peripheral neuropathy. The MNSI Examination score ranges from 0 to 8, with a score of ≥2 considered diagnostic of diabetic peripheral neuropathy. Higher scores on both components indicate greater neuropathy severity, whereas lower scores following the intervention indicate improvement in peripheral nerve function and neuropathic symptoms.

    Time frame: From enrollment to 4 weeks and then to the end of treatment at 8 weeks.

  2. Vibration perception threshold (VPT)

    Vibration perception threshold will be assessed using a digital biothesiometer to evaluate large-fiber peripheral nerve function in participants with diabetic peripheral neuropathy. The biothesiometer measures the minimum vibration intensity perceived by the participant and is recorded in volts (V). Assessments will be performed at baseline, 4 weeks, and 8 weeks. The VPT score ranges from 0 to 50 volts, with higher values indicating poorer vibration perception and more severe peripheral nerve dysfunction. A VPT value of ≥25 volts will be used as the diagnostic threshold for diabetic peripheral neuropathy. A reduction in VPT values following the intervention indicates improved sensory nerve function and reduced neuropathy severity.

    Time frame: From enrollment to 4 weeks and then to the end of treatment at 8 weeks.

  3. Balance and Gait Mobile Application

    Balance and gait performance will be assessed using the validated Balance and Gait mobile application. The application utilizes the smartphone's built-in inertial sensors (accelerometer and gyroscope) to objectively evaluate postural stability and gait performance. Assessments will be conducted at baseline, 4 weeks, and 8 weeks. The application provides quantitative measures of balance and gait, including postural sway, gait stability, walking speed, cadence, stride characteristics, and an overall balance/gait performance score, depending on the application outputs. Higher balance and gait scores (or improved gait parameters, such as increased gait speed and reduced postural sway) indicate better functional mobility and postural stability, whereas poorer scores indicate greater balance impairment and increased risk of falls.

    Time frame: From enrollment to 4 weeks and then to the end of treatment at 8 weeks.

  4. Glycated Hemoglobin (HbA1c)

    Glycated hemoglobin (HbA1c) will be measured using a standardized laboratory assay to assess long-term glycemic control. HbA1c reflects the average blood glucose concentration over the preceding 2-3 months and is reported as a percentage (%) of total hemoglobin. Assessments will be performed at baseline, 4 weeks, and 8 weeks. HbA1c values range from approximately 4% to 14% or higher, with lower values indicating better glycemic control. In accordance with the American Diabetes Association (ADA) criteria, an HbA1c level of \<5.7% is considered normal, 5.7%-6.4% indicates prediabetes, and ≥6.5% is diagnostic of diabetes mellitus. Participants eligible for this study will have baseline HbA1c values between 6.5% and 9.0%. A reduction in HbA1c following the intervention will indicate improved long-term glycemic control.

    Time frame: From enrollment to 4 weeks and then to the end of treatment at 8 weeks.

  5. Norfolk Quality of Life-Diabetic Neuropathy (QOL-DN)

    Health-related quality of life will be assessed using the Norfolk Quality of Life-Diabetic Neuropathy (Norfolk QOL-DN) questionnaire, a validated patient-reported outcome measure specifically designed to evaluate the impact of diabetic peripheral neuropathy on physical functioning and quality of life. The questionnaire assesses symptoms and functional limitations across multiple domains, including physical functioning/large-fiber neuropathy, activities of daily living, symptoms, small-fiber neuropathy, and autonomic neuropathy. Assessments will be conducted at baseline, 4 weeks, and 8 weeks. The Norfolk QOL-DN total score ranges from -4 to 136, with higher scores indicating poorer health-related quality of life and greater neuropathy-related impairment, whereas lower scores indicate better quality of life and reduced symptom burden. A decrease in the total score following the intervention will be interprete

    Time frame: From enrollment to 4 weeks and then to the end of treatment at 8 weeks.

  6. Acceptability of Intervention Measure (AIM)

    Acceptability of the exercise intervention will be assessed using the Acceptability of Intervention Measure (AIM), a validated implementation outcome instrument. The AIM consists of 4 items rated on a 5-point Likert scale ranging from 1 (Completely Disagree) to 5 (Completely Agree), yielding a total score of 4-20. Higher scores indicate greater participant-perceived acceptability of the intervention. The AIM will be administered at the completion of the 8-week intervention.

    Time frame: At the end of treatment at 8 weeks.

  7. Intervention Appropriateness Measure (IAM)

    Perceived appropriateness of the exercise intervention will be assessed using the Intervention Appropriateness Measure (IAM). The IAM consists of 4 items rated on a 5-point Likert scale ranging from 1 (Completely Disagree) to 5 (Completely Agree), resulting in a total score of 4-20. Higher scores indicate that participants perceive the intervention to be more appropriate and suitable for managing diabetic peripheral neuropathy. The IAM will be administered at the completion of the 8-week intervention.

    Time frame: At the end of treatment after 8 weeks of intervention

  8. Feasibility of Intervention Measure (FIM)

    Feasibility of the exercise intervention will be evaluated using the Feasibility of Intervention Measure (FIM). The FIM consists of 4 items rated on a 5-point Likert scale ranging from 1 (Completely Disagree) to 5 (Completely Agree), yielding a total score of 4-20. Higher scores indicate greater perceived feasibility of implementing the intervention in clinical practice. The FIM will be administered at the completion of the 8-week intervention.

    Time frame: At the end of treatment after 8 weeks of intervention.

07

Study locations

1 site
  • Pakistan Railways General Hospital and Mediplex Healthcare Center
    Rawalpindi, 46210, Pakistan
08

References and documents

Publications

  • Jamali A, Shahrbanian S, Morteza Tayebi S. The Effects of Exercise Training on the Brain-Derived Neurotrophic Factor (BDNF) in the Patients with Type 2 Diabetes: A Systematic Review of the Randomized Controlled Trials. J Diabetes Metab Disord. 2020 May 6;19(1):633-643. doi: 10.1007/s40200-020-00529-w. eCollection 2020 Jun. PubMed 32550216 ↗

Study documents

PDFs hosted by the registry, ClinicalTrials.gov.

Individual participant data

Plan to share: No — Individual participant data collected during the trial will not be made publicly available. Study findings will be disseminated through peer-reviewed publications and conference presentations. All data will remain securely stored by the research team in accordance with institutional policies and ethical guidelines.

09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Start is estimated for Sep 2026; primary completion for Sep 2027, 12 months later.

Of 138 non-industry interventional studies with no phase under Diabetic Neuropathies, half reached primary completion within 11 months of starting (the median), counting those still running; a quarter within 6 and three quarters within 24. This study's planned 12 months is close to that.

Counting every sponsor, half of 153 studies reached it within 11 months; a quarter within 6 and three quarters within 28.

How these figures are worked out, and which studies are left out of them.

Registered
Apr 15, 2026
First posted
Jun 30, 2026
StartEst.
Sep 2026
Primary completionEst.
Sep 2027
CompletionEst.
Dec 2027
Last update
Jun 30, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Jun 30, 2026, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT07675720
Responsible party
Sponsor
First posted
Jun 30, 2026
Start date
Sep 2026 (estimated)
Primary completion
Sep 2027 (estimated)
Completion
Dec 2027 (estimated)
Last update
Jun 30, 2026

Study contacts

Waqar Ahmed Awan, Ph.D
Contact
waqar.ahmed@riphah.edu.pk
+923335348846
Muhammad Ashar Rafi, MS-NMPT
Contact
ashar.special51@gmail.com
+923083407837
Muhammad Ashar Rafi, MS-NMPT
principal investigator · Riphah International University

Oversight

Data monitoring committee
Yes
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is not yet recruiting, as verified in Jun 2026. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion